



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: June 9, 2006

To: NCCTG Primary Clinical Research Associates

From: Lori K. Bratvold
Protocol Development Coordinator

Re: N027D, A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

The attached Grade 4 or 5 non-AER reportable events/hospitalization form has been updated to include remote data entry instructions. Please replace your current version of this form with the attached revised version.

If you have any questions, please feel free to contact me at 507/266-3549.

LB/dg
Enclosure